Neuropathic Pain - Epidemiology forecast- 2030

DelveInsight's 'Neuropathic Pain - Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical and forecasted Neuropathic Pain epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geographies Covered
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2017-2030

Neuropathic Pain Understanding
The DelveInsight Neuropathic Pain epidemiology report gives a thorough understanding of the Neuropathic Pain by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Neuropathic Pain in the US, Europe, and Japan. The report covers the detailed information of the Neuropathic Pain epidemiology scenario in seven major countries (US, EU5, and Japan).

Neuropathic Pain Epidemiology Perspective by DelveInsight
The Neuropathic Pain epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Neuropathic Pain epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Neuropathic Pain epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2017 to 2030. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Neuropathic Pain Detailed Epidemiology Segmentation
The Neuropathic Pain epidemiology covered in the report provides historical as well as forecasted Neuropathic Pain epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) and Japan from 2017 to 2030.
The DelveInsight Neuropathic Pain report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

Scope of the Report
• The Neuropathic Pain report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• The Neuropathic Pain Epidemiology Report and Model provide an overview of the risk factors and global trends of Neuropathic Pain in the seven major markets (7MM:US, France, Germany, Italy, Spain, UK, and Japan)
• The report provides insight about the historical and forecasted patient pool of Neuropathic Pain in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
• The report helps to recognize the growth opportunities in the 7MM with respect to the patient population
• The report assesses the disease risk and burden and highlights the unmet needs of Neuropathic Pain
• The report provides the segmentation of the Neuropathic Pain epidemiology

Report Highlights
• 11-Year Forecast of Neuropathic Pain epidemiology
• 7MM Coverage
• Total Cases of Neuropathic Pain
• Total Cases of Neuropathic Pain according to segmentation
• Diagnosed cases of Neuropathic Pain

KOL- Views
We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered
• What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Neuropathic Pain?
• What are the key findings pertaining to the Neuropathic Pain epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017-2030)?
• What would be the total number of patients of Neuropathic Pain across the 7MM during the forecast period (2017-2030)?
• Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017-2030)?
• At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017-2030)?
• What is the disease risk, burden and unmet needs of the Neuropathic Pain?
• What are the currently available treatments of Neuropathic Pain?

Reasons to buy
• The Neuropathic Pain Epidemiology report will allow the user to -
• Develop business strategies by understanding the trends shaping and driving the global Neuropathic Pain market
• Quantify patient populations in the global Neuropathic Pain market to improve product design, pricing, and launch plans
• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Neuropathic Pain therapeutics in each of the markets covered
• Understand the magnitude of Neuropathic Pain population by its epidemiology
• The Neuropathic Pain Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Key Assessments
• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Please Note: It will take 5-7 business days to complete the report upon order confirmation.


1. Key Insights
2. Executive Summary of Neuropathic Pain
3. Neuropathic Pain: Disease Background and Overview
3.1. Introduction
3.2. Sign and Symptoms
3.3. Pathophysiology
3.4. Risk Factors
3.5. Diagnosis
4. Patient Journey
5. Epidemiology and Patient Population
5.1. Epidemiology Key Findings
5.2. Assumptions and Rationale: 7MM
5.3. Epidemiology Scenario: 7MM
5.3.1. Neuropathic Pain Epidemiology Scenario in the 7MM (2017- 2030)
5.4. United States Epidemiology
5.4.1. Neuropathic Pain Epidemiology Scenario in the United States (2017- 2030)
5.5. EU-5 Country-wise Epidemiology
5.5.1. Germany Epidemiology
5.5.1.1. Neuropathic Pain Epidemiology Scenario in Germany (2017- 2030)
5.5.2. France Epidemiology
5.5.2.1. Neuropathic Pain Epidemiology Scenario in France (2017- 2030)
5.5.3. Italy Epidemiology
5.5.3.1. Neuropathic Pain Epidemiology Scenario in Italy (2017- 2030)
5.5.4. Spain Epidemiology
5.5.4.1. Neuropathic Pain Epidemiology Scenario in Spain (2017- 2030)
5.5.5. United Kingdom Epidemiology
5.5.5.1. Neuropathic Pain Epidemiology Scenario in the United Kingdom (2017-2030)
5.6. Japan Epidemiology
5.6.1. Neuropathic Pain Epidemiology Scenario in Japan (2017- 2030)
6. Treatment Algorithm, Current Treatment, and Medical Practices
6.1. Neuropathic Pain Treatment and Management
6.2. Neuropathic Pain Treatment Algorithm
7. KOL Views
8. Unmet Needs
9. Appendix
9.1. Bibliography
9.2. Report Methodology
10. DelveInsight Capabilities
11. Disclaimer
12. About DelveInsight
*The table of contents is not exhaustive; will be provided in the final report
Table 1 Neuropathic Pain Epidemiology in 7MM (2017-2030)
Table 2 Neuropathic Pain Diagnosed and Treatable Cases in 7MM (2017-2030)
Table 3 Neuropathic Pain Epidemiology in the United States (2017-2030)
Table 4 Neuropathic Pain Diagnosed and Treatable Cases in the United States (2017-2030)
Table 5 Neuropathic Pain Epidemiology in Germany (2017-2030)
Table 6 Neuropathic Pain Diagnosed and Treatable Cases in Germany (2017-2030)
Table 7 Neuropathic Pain Epidemiology in France (2017-2030)
Table 8 Neuropathic Pain Diagnosed and Treatable Cases in France (2017-2030)
Table 9 Neuropathic Pain Epidemiology in Italy (2017-2030)
Table 10 Neuropathic Pain Diagnosed and Treatable Cases in Italy (2017-2030)
Table 11 Neuropathic Pain Epidemiology in Spain (2017-2030)
Table 12 Neuropathic Pain Diagnosed and Treatable Cases in Spain (2017-2030)
Table 13 Neuropathic Pain Epidemiology in the United Kingdom (2017-2030)
Table 14 Neuropathic Pain Diagnosed and Treatable Cases in the United Kingdom (2017-2030)
Table 15 Neuropathic Pain Epidemiology in Japan (2017-2030)
Table 16 Neuropathic Pain Diagnosed and Treatable Cases in Japan (2017-2030)
Figure 1 Neuropathic Pain Epidemiology in 7MM (2017-2030)
Figure 2 Neuropathic Pain Diagnosed and Treatable Cases in 7MM (2017-2030)
Figure 3 Neuropathic Pain Epidemiology in the United States (2017-2030)
Figure 4 Neuropathic Pain Diagnosed and Treatable Cases in the United States (2017-2030)
Figure 5 Neuropathic Pain Epidemiology in Germany (2017-2030)
Figure 6 Neuropathic Pain Diagnosed and Treatable Cases in Germany (2017-2030)
Figure 7 Neuropathic Pain Epidemiology in France (2017-2030)
Figure 8 Neuropathic Pain Diagnosed and Treatable Cases in France (2017-2030)
Figure 9 Neuropathic Pain Epidemiology in Italy (2017-2030)
Figure 10 Neuropathic Pain Diagnosed and Treatable Cases in Italy (2017-2030)
Figure 11 Neuropathic Pain Epidemiology in Spain (2017-2030)
Figure 12 Neuropathic Pain Diagnosed and Treatable Cases in Spain (2017-2030)
Figure 13 Neuropathic Pain Epidemiology in the United Kingdom (2017-2030)
Figure 14 Neuropathic Pain Diagnosed and Treatable Cases in the United Kingdom (2017-2030)
Figure 15 Neuropathic Pain Epidemiology in Japan (2017-2030)
Figure 16 Neuropathic Pain Diagnosed and Treatable Cases in Japan (2017-2030)
*The table of contents is not exhaustive; will be provided in the final report

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook